Oppenheimer assumed coverage on shares of Alumis (NASDAQ:ALMS - Free Report) in a research report sent to investors on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $32.00 price target on the stock.
Other research analysts have also recently issued reports about the stock. Baird R W upgraded shares of Alumis to a "strong-buy" rating in a report on Thursday, October 31st. Robert W. Baird assumed coverage on Alumis in a report on Thursday, October 31st. They issued an "outperform" rating and a $25.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $26.00 target price on shares of Alumis in a report on Monday, January 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a report on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Alumis presently has an average rating of "Buy" and an average price target of $27.57.
Get Our Latest Report on Alumis
Alumis Trading Down 1.9 %
NASDAQ:ALMS traded down $0.14 during midday trading on Thursday, reaching $7.34. 71,869 shares of the company traded hands, compared to its average volume of 159,733. The company has a fifty day moving average price of $8.06 and a 200 day moving average price of $10.39. Alumis has a twelve month low of $6.29 and a twelve month high of $13.53.
Hedge Funds Weigh In On Alumis
A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new stake in shares of Alumis in the third quarter worth about $3,266,000. State Street Corp acquired a new position in shares of Alumis during the 3rd quarter worth about $866,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Alumis during the third quarter worth approximately $1,160,000. Towerview LLC boosted its position in shares of Alumis by 22.6% in the third quarter. Towerview LLC now owns 380,000 shares of the company's stock valued at $4,058,000 after acquiring an additional 70,000 shares during the period. Finally, Stifel Financial Corp bought a new position in shares of Alumis during the 3rd quarter worth about $931,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
